Opinion: TSMC Is a Better Buy Than Any of the "Magnificent Seven" Stocks Right Now

TSMC is gaining nearly 36% year-to-date (+78% over 12 months), outpacing every Magnificent Seven stock, as AI-driven chip demand boosts foundry leverage. Q2 results showed revenue of $40.2B (+33.7% YoY) with 67.7% gross margin and a 55.6% net profit margin. TSMC began producing chips on its new 2-nanometer process in Q2 (3% of wafer revenue then), and plans to scale as well as expand Arizona investment with an additional $100B (total Arizona spend $265B), supporting an upbeat outlook for AI silicon and accelerators.

Analysis

The cleanest read-through is that TSM is the toll booth on AI capex, while the merchant AI chip names are increasingly just one of several traffic sources. Even if hyperscalers keep shifting more inference and training to in-house silicon, that still expands wafer starts at advanced nodes, so TSM monetizes the whole ecosystem rather than betting on a single winner. The second-order loser is the “scarcity premium” in NVDA: if customers internalize more silicon design, the market may start valuing Nvidia more like a high-growth platform and less like an irreplaceable bottleneck.

The near-term risk is that this becomes a crowding trade: TSM has already re-rated, so the next leg likely needs another proof point on 2nm yields, pricing, or a stronger 2026 capex guide. The Arizona build is strategically positive but near-term FCF negative; if management leans too hard into U.S. capacity, the market could start haircutting margins for execution risk and slower return on incremental capital. Over 6-18 months, the real thesis hinge is whether TSM preserves node leadership versus Intel/Samsung rather than whether AI demand exists.

Consensus is probably underweighting how diversified the demand base is, but overestimating how linear the equity upside will be from here. TSM is the better expression of AI infrastructure spending than any single Mag-7 name, yet at this valuation the stock needs smooth ramp execution, not just good industry headlines. The contrarian setup is that TSM can keep compounding while NVDA’s multiple becomes more sensitive to any evidence of customer substitution into custom ASICs.

Key Decisions for Investors

• Buy TSM on 3-5% pullbacks over the next 2-4 weeks; hold for 3-6 months. Upside case is continued 2nm adoption and AI capex breadth; thesis breaks if 2nm revenue mix stalls or gross margin inflects down from the high-60s.
• Relative-value trade: long TSM / short NVDA on a beta-adjusted basis for 1-3 months. This works if the market rotates toward foundry bottlenecks over accelerator scarcity; cover if NVDA guidance or backlog re-accelerates faster than expected.
• Use INTC as the structural short for the 6-12 month horizon if you want a cleaner winner/loser on process leadership. The trade is invalidated if Intel demonstrates credible foundry yield recovery or customer wins at leading nodes.
• Set an alert on TSM management commentary around 2nm yield and Arizona capex efficiency at the next print. A softer ramp or rising U.S. build cost would be the main catalyst to reduce exposure.